Amphastar Pharmaceuticals (AMPH) Profit After Tax (2013 - 2026)

Amphastar Pharmaceuticals has reported Profit After Tax for 14 years, with the latest figure at $30.3 million in Q2 2026.

• On a quarterly basis, Profit After Tax fell 2.2% year-over-year to $30.3 million in Q2 2026; TTM through Jun 2026 was $78.5 million, a 41.69% decrease from a year earlier, with the FY2025 full-year figure at $98.1 million, down 38.73% from the prior year.
• Profit After Tax was $30.3 million for Q2 2026 at Amphastar Pharmaceuticals, up from $6.4 million in the prior quarter.
• The five-year high for Profit After Tax was $49.6 million in Q3 2023, with the low at $6.4 million in Q1 2026.
• Average Profit After Tax over 5 years is $29.1 million, with a median of $28.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Profit After Tax soared 381.11% in 2022, then sank 74.61% in 2026.
• Over 5 years, Profit After Tax stood at $34.0 million in 2022, then advanced by 7.95% to $36.7 million in 2023, then advanced by 3.52% to $38.0 million in 2024, then sank by 35.65% to $24.4 million in 2025, then gained by 24.23% to $30.3 million in 2026.
• The last three Profit After Tax figures came in at $30.3 million (Q2 2026), $6.4 million (Q1 2026), and $24.4 million (Q4 2025), per Business Quant data.